CYP2C19 genotype and cardiovascular events [2]

JAMA

Volumn 307, Issue 14, 2012, Pages 1482-1483

  Mega, Jessica L ^a   Topol, Eric J ^b   Sabatine, Marc S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ADVERSE OUTCOME; ALLELE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY STENT; CYP2C19 GENE; DRUG EFFECT; DRUG METABOLISM; DRUG RESPONSE; GENE; GENE LOSS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LETTER; LOSS OF FUNCTION MUTATION; PHARMACOGENETICS; PRIORITY JOURNAL; STENT THROMBOSIS; BLEEDING; GENETICS; METABOLISM; NOTE; THROMBOCYTE AGGREGATION;

ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; HEMORRHAGE; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84859532994     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.444     Document Type: Letter

References (5)

1. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA. 2011;306(24):2704-2714.
2. Leon MB, Baim DS, Popma JJ, et al Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339(23):1665-1671. (Pubitemid 28550691)
3. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821-1830.
4. Paré G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18):1704-1714.
5. Hulot JS, Collet JP, Montalescot G. Genetic substudy of the PLATO trial. Lancet. 2011;377(9766):637-638.